Eisai
Eisai Co., Ltd., commonly referred to as Eisai, is a prominent global pharmaceutical company headquartered in Japan. Established in 1941, Eisai has made significant strides in the healthcare industry, focusing on the discovery, development, and marketing of innovative medicines. With major operational regions across Asia, Europe, and North America, the company is dedicated to addressing unmet medical needs, particularly in neurology and oncology. Eisai's core products include treatments for Alzheimer's disease and various cancers, distinguished by their commitment to patient-centric solutions. The company has achieved notable recognition for its research and development efforts, positioning itself as a leader in the pharmaceutical sector. With a strong emphasis on ethical practices and collaboration, Eisai continues to enhance its market presence while striving to improve the quality of life for patients worldwide.
DitchCarbon Score
How does Eisai's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eisai's score of 41 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Eisai's reported carbon emissions
Eisai Co., Ltd., headquartered in Japan, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas (GHG) emissions. Although specific emissions data for the most recent year is not available, the company has established clear reduction targets. Eisai aims to reduce its absolute Scope 1 and Scope 2 GHG emissions by 55% by fiscal year 2030, using fiscal year 2019 as the base year. Additionally, the company is committed to reducing its Scope 3 emissions, specifically from purchased goods and services, by 27.5% within the same timeframe. Eisai's long-term goal includes achieving Net-Zero emissions by 2050, demonstrating its commitment to sustainability and climate action. These targets align with industry standards and are consistent with the reductions necessary to limit global warming to 1.5°C. The company has also previously committed to a 30% reduction in Scope 1 and Scope 2 emissions by fiscal year 2030 from a fiscal year 2016 base year, indicating a progressive approach to its climate strategy. Overall, Eisai's initiatives reflect a strong commitment to addressing climate change and reducing its carbon footprint in the pharmaceutical sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eisai is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
